Pancreatic Cancer Research

ResearcherAbramson Cancer CenterActive in the last 2 years

Katherine L. Nathanson

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6740-0901; OpenAlex author ID A5072490052. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 10

  1. Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Tria… Last author DOI 10.1001/jamaoncol.2026.0870↗
  2. Assessment of barriers to pancreatic cancer surveillance in high-risk individuals. Co-author DOI 10.1002/jgc4.70117↗
  3. Integration of Germline Genetic Testing Into Routine Clinical Practice for Patients With Pancreatic Adenocarcinoma. Co-author DOI 10.1200/op.24.00356↗
  4. The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Ruca… Co-author DOI 10.1158/1078-0432.ccr-23-1467↗
  5. Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, B… Co-author DOI 10.1200/jco.21.00003↗
  6. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Co-author DOI 10.1038/s41416-019-0582-7↗
  7. Retrospective Survival Analysis of Patients With Resected Pancreatic Ductal Adenocarcinoma and a Germline BRCA or PALB2 Mutation. Co-author DOI 10.1200/po.18.00271↗
  8. Association of Pancreatic Cancer Susceptibility Variants with Risk of Breast Cancer in Women of European and African Ancestry. Co-author DOI 10.1158/1055-9965.epi-17-0755↗
  9. Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline BRCA or PALB2 Mutations. Co-author DOI 10.1200/po.17.00152↗
  10. PALB2 mutations in familial breast and pancreatic cancer. Co-author DOI 10.1007/s10689-011-9426-1↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Susan M. Domchek · 9 shared papers, 2011–2026 · strength 1.27
  2. Kim A. Reiss · 7 shared papers, 2018–2026 · strength 1.02
  3. Mark H. O’Hara · 4 shared papers, 2019–2026 · strength 0.59
  4. Timothy J. Brown · 2 shared papers, 2023–2026 · strength 0.39
  5. Zain M. Hannan · 2 shared papers, 2021–2026 · strength 0.34
  6. Robert H. Vonderheide · 2 shared papers, 2021–2026 · strength 0.34
  7. Shun Yu · 3 shared papers, 2018–2020 · strength 0.29
  8. Thomas Benjamin Karasic · 2 shared papers, 2021–2023 · strength 0.26
  9. Kelsey S. Lau‐Min · 1 shared paper, 2025 · strength 0.23
  10. Grace Snyder · 1 shared paper, 2025 · strength 0.22
  11. Bryson W. Katona · 1 shared paper, 2025 · strength 0.22
  12. Max Miller Wattenberg · 2 shared papers, 2020–2021 · strength 0.22
  13. Gregory Lawrence Beatty · 2 shared papers, 2020–2021 · strength 0.22
  14. Peter James O'Dwyer · 2 shared papers, 2019–2020 · strength 0.20
  15. Jacob Edward Till · 1 shared paper, 2023 · strength 0.16
  16. Erica L. Carpenter · 1 shared paper, 2023 · strength 0.16
  17. Mark Alan Rosen · 1 shared paper, 2020 · strength 0.11
  18. Parul Agarwal · 1 shared paper, 2019 · strength 0.09
  19. Ronac Mamtani · 1 shared paper, 2019 · strength 0.09
  20. Shengfeng Wang · 1 shared paper, 2018 · strength 0.08
  21. Dezheng Huo · 1 shared paper, 2018 · strength 0.08
  22. Wei Zheng · 1 shared paper, 2018 · strength 0.08
  23. Erin Wysong Hofstatter · 1 shared paper, 2011 · strength 0.03
  24. Nadine Tung · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.